Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (SenPET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04536454
Recruitment Status : Recruiting
First Posted : September 2, 2020
Last Update Posted : May 11, 2021
Sponsor:
Information provided by (Responsible Party):
University Hospital Tuebingen

Brief Summary:
It is of particular interest to find out whether it is possible to use the novel radiotracer [18F]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer [18F]FPyGal, is called tumor senescence.

Condition or disease Intervention/treatment Phase
Cancer Drug: [18F]FPyGal Phase 1 Phase 2

Detailed Description:

The so-called tumor senescence is described as a resistance mechanism, which can be the basis for the non-response to most common chemotherapies. It is believed that the identification of so-called senescent tumors could improve treatment strategies for solid tumors and, in particular, avoid inefficient treatment of patients with highly toxic drugs.

The aim of this study is to investigate the safety, radiation exposure (dosimetry) and diagnostic accuracy of the novel diagnostic substance [18F]FPyGal if it is used before tumor imaging imaging (here: positron emission tomography combined with magnetic resonance imaging (PET / MRT) or in combination with computed tomography (PET / CT)).

Diagnostic substances used in imaging such as [18F]FPyGal are known as radiotracers, since their distribution in the tumor tissue can provide information about the special tumor biological processes taking place there.

In the context of this study, it is of particular interest to find out whether it is possible to use the novel radiotracer [18F]FPyGal to detect areas after standard tumor therapy that contain particularly resistant (therapy-resistant) tumor cells. This resistance phenomenon in tumor tissues, which may be visualized with the radiotracer [18F]FPyGal, is called tumor senescence.

The latest research results show that senescent tumor cells can not only evade different forms of chemotherapy or radiation therapy. Senescent tumor cells can also cause the cancer to come back later. That is why current therapeutic research is concentrating on developing new approaches to combat such senescent tumor cells. For this it is relevant to be able to first diagnose senescent tumor cells as well as possible using imaging.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 32 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: A Phase 1/2, Open-label Study to Assess Safety, Tolerability, Biodistribution, Radiation Dosimetry and PET Imaging Characteristics of [18F]FPyGal in Comparison to in Vitro Diagnostics for the Assessment of Senescence in Oncological Patients
Actual Study Start Date : April 28, 2021
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: [18F]FPyGal

Cancer patients will first be treated with a tumor type-specific neo-adjuvant chemotherapy regimen (standard-of-care); subsequently, they will undergo surgical resection of their primary tumors in a curative intention.

After the end of the neo-adjuvant therapy a tracer injection with [18F]FPyGal solution will be administered (study intervention). Immediately after the injection a dynamic PET/MR imaging of the tumor sites including heart or large arterial blood pools will be conducted over 90 minutes.

Drug: [18F]FPyGal
Radiotracer for PET-imaging
Other Name: non-invasive imaging of tumor senescence




Primary Outcome Measures :
  1. Incidence and severity of adverse events (AEs) [ Time Frame: 7 days ]
    Incidence and severity of adverse events (AEs) (CTCAE V5.0) over 7 days Grade 1: no interruption; Grade 2: interrupt until Grade 0/1; Grade 3 and >3: interruption of study


Secondary Outcome Measures :
  1. Number of patients exhibiting positive signals for senescent tumor cells in PET-imaging and/or tumor histopathology [ Time Frame: through study completion, an average of 6 month ]
    Positive [18F]FPyGal-PET-imaging of patient's tumor will be correlated with histopathology using senescence specific biomarkers against SABG (senescence-associated ß-galactosidase), p16, p21, and p53



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female patients ≥ 18 years of age at the time of signing the informed consent
  • Patients with locally advanced primary non-operable solid tumors (AEGs, rectum cancers, NSCLCs, NUT midline carcinomas (NMC))
  • Eastern Cooperative Oncology Group Performance (ECOG) Status ≤ 2
  • Adequate bone marrow, renal, and hepatic function defined by laboratory tests within 14 days prior to study treatment:

    • Neutrophil count ≥ 1,500/mm3
    • Platelet count ≥ 100,000/µl
    • Bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • ALT (alanine transaminase) and AST (aspartate transaminase) ≤ 2.5 x ULN
    • PT-INR (prothrombin time and international normalized ratio) /PTT (partial thromboplastin time)= ≤ 1.5 x ULN
    • Creatine kinase ≤ 2.5 x ULN
    • Serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min
  • Patients scheduled for neo-adjuvant (radio-) chemotherapy and subsequent tumor surgery (Groups a-c) or tumor biopsy (Group d)
  • Understand and voluntarily sign an informed consent document prior to any study related assessments/ procedures.
  • Able to adhere to the study visit schedule and other protocol requirements
  • Consent to practice double-barrier contraception until end of the study (28 days after last [18F]FPyGal injection)

    • Females of childbearing potential (FCBP) must agree

      • to use two reliable forms of contraception simultaneously or practice complete abstinence from heterosexual contact for at least 28 days before starting study drug, while participating in the study (including dose interruptions), and for at least 28 days after end of study treatment and must agree to pregnancy testing during this timeframe
      • to abstain from breastfeeding during study participation and 7 days after end of study drug administration.
    • Males must agree

      • to use a latex condom during any sexual contact with FCBP while participating in the study and for at least 28 days after end of study treatment, even if he has undergone a successful vasectomy
      • to refrain from donating semen or sperm while participating in the study and for at least 28 days after end of study treatment.

Exclusion Criteria:

  • Any contraindication for MRI (impaired renal function and / or known hypersensitivity to gadolinium-containing contrast agent are not considered as contraindication, since then imaging will be performed without gadolinium contrast agent).
  • Known hypersensitivity to [18F]FPyGal or its components or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product
  • Administration of any kind of PET tracer within a period corresponding to 8 half-lives of the representative radionuclide (e.g. for fluorine-18: 109.77 min, 8x109.77 min =14.7 h)
  • Persistent toxicity (>Grade 2) according to Common Terminology Criteria for Adverse Events [CTCAE] version 5.0, caused by previous cancer therapy, excluding alopecia
  • Clinical signs of active infection (> Grade 2 according to CTCAE version 5.0)
  • History of HIV infection
  • Immunocompromised patients
  • Active or chronic viral hepatitis (HBV or HCV)
  • History of autoimmune disease
  • History of relevant CNS pathology or current relevant CNS (central nervous system) pathology (e.g. seizure, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis, coordination or movement disorder) Epilepsy requiring pharmacologic treatment
  • Therapeutic anticoagulation therapy
  • Major surgery within 4 weeks of starting study treatment. Patients must have recovered from any effects of major surgery.
  • Patients receiving any systemic chemotherapy or radio-therapy within 2 weeks prior to study treatment or a longer period depending on the defined characteristics of the agents used
  • Heart failure NYHA (New York Heart Association) III/IV
  • Severe obstructive or restrictive ventilation disorder
  • Known history of GI-perforation
  • Patients not able to declare meaningful informed consent on their own
  • Women during pregnancy and lactation; female patients of childbearing potential or male patients with female partners of childbearing potential not willing to practice effective contraception by using a double-barrier method from Day 0 until 28 days post-dose.
  • Male patients planning to donate sperm while participating in the study and for at least 28 days after end of study treatment.
  • Participation in other clinical trials or observation period of competing trials

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04536454


Contacts
Layout table for location contacts
Contact: Christian la Fougere, MD +49-7071 29-0 christian.lafougere@med.uni-tuebingen.de
Contact: Ulrich M Lauer, MD +49-7071 29-0 ulrich.lauer@med.uni-tuebingen.de

Locations
Layout table for location information
Germany
University Hospital of Tübingen Recruiting
Tübingen, BW, Germany, 72076
Contact: Christian la Fougere, MD    +49 7071 29-86553    christian.lafougere@med.uni-tuebingen   
Contact: Lars Zender, MD    +49 7071 29-83675    lars.zender@med.uni-tuebingen.de   
Sponsors and Collaborators
University Hospital Tuebingen
Investigators
Layout table for investigator information
Study Director: Lars Zender, MD University Hospital of Tübingen
Layout table for additonal information
Responsible Party: University Hospital Tuebingen
ClinicalTrials.gov Identifier: NCT04536454    
Other Study ID Numbers: iFIT-01
First Posted: September 2, 2020    Key Record Dates
Last Update Posted: May 11, 2021
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospital Tuebingen:
Senescence
[18F]FPyGal
PET / CT
PET / MRI